Gutscheinbedingungen

*Gültig bis 18.08.2026 auf (fast) alles. Ausgeschlossen sind Smartboxen, Zeitschriften, Tickets, Lebensmittel, Gaming-Elektroartikel, Tinte/Toner, Gutscheine, Geschenkkarten, Blumen und Abos | Einlösbar in allen Buchhandlungen von Orell Füssli, Barth Bücher, Buchladen Rapunzel, Schuler Orell Füssli, Stauffacher und ZAP unter Vorweisung des Gutscheins, auf www.orellfüssli.ch durch Eingabe des Gutscheincodes. Beim Service „eBooks verschenken“ und bei eBook-Käufen via eReader nicht einlösbar | Mindesteinkaufswert: Fr. 100.- | Nicht mit anderen Rabatten kumulierbar.

Produktbild: Molecular Insights Into Proteinopathies
Vorbesteller Neu

Molecular Insights Into Proteinopathies Increased Scope from Neurodegeneration to Other Pathologies of the Brain

Fr. 218.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

01.10.2026

Herausgeber

Eva Zerovnik + weitere

Verlag

Elsevier

Seitenzahl

350

Maße (L/B)

23.5/19.1 cm

Gewicht

449 g

Sprache

Englisch

ISBN

978-0-443-34176-2

Beschreibung

Portrait

Eva Žerovnik is known in the field of protein folding and in neuroscience. She publishes in both fields, as well as biophysics. Her educational background is in physical chemistry, structural biology, biochemistry and neurosciences, therefore her work is multidisciplinary. She is currently Professor of Biochemistry at Jožef Stefan International Postgraduate School and scientific advisor at Institut Jožef Stefan, Slovenia. She has led collaborations with some leading labs such as Medical School, Nottingham, Medical School, Newcastle upon Tyne, Biomolecular NMR, Sheffield, UK, Department of Physics, Drexel University USA, Brain and Mind Institute, Lausanne, CH and IRCCS Fatebenefratelli, Brescia, Italy.

Robert Layfield is a Professor of Protein Biochemistry at the University of Nottingham. He recently completed a 4-year term as Head of the Physiology, Pharmacology and Neuroscience Research Division, within the School of Life Sciences. He was an MND Association BRAP (Biomedical Research Advisory Panel) member from 2018-2022 and has a long-standing research interest in cellular mechanisms of removal of defective proteins in Alzheimer’s disease, Parkinson’s and MND. His group made the first mechanistic demonstrations of proteostasis defects in Alzheimer’s disease.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

01.10.2026

Herausgeber

Verlag

Elsevier

Seitenzahl

350

Maße (L/B)

23.5/19.1 cm

Gewicht

449 g

Sprache

Englisch

ISBN

978-0-443-34176-2

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Molecular Insights Into Proteinopathies
  • Part 1. Protein aggregation in different proteinopathies
    1. Amyloid-pore hypothesis: prefibrillar oligomers interaction with membranes; a generic cause of neurodegeneration?
    2. In vivo molecular brain imaging of metabolic (dys)function and protein accumulation in neurodegenerative disease
    3. Amyotrophic lateral sclerosis: Relevance of protein aggregation of TDP-43 and mechanisms of toxicity
    4. Cystatin C amyloid angiopathy (CAA) and AD: Interaction of cystatins oligomers with A-beta
    5. Protein aggregation and disturbed proteostasis in mental illness, stress on shizophrenia
    6. Protein aggregation in progressive myoclonus epilepsies, in particular EPM1
    7. Model amyloid proteins: What are the lessons to understand proteinopathies

    Part 2. Common signaling pathways and biomarkers of disease
    8. The integrated stress response: from mechanism to disease
    9. Comparison of AD and schizophrenia: From signaling to biomarkers
    10. Oxidative stress and mitochondrial decline in common to several proteinopathies
    11. Irisin reduces amyloid-b by inducing the release of neprilysin from astrocytes following down regulation of ERK-STAT3 signaling
    12. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder

    Part 3. Small molecules as modulators of the key processes in proteinopathies
    13. Trem2 signaling modulators to treat neurodegenerative disease
    14. Small molecules modulators of protein aggregation and toxicity: antioxidants and polyphenol compounds
    15. Therapeutic Strategies to Mitigate the Toxicity of ¿-Synuclein Oligomers in Parkinson's Disease
    16. Repurposed drugs that modulate proteinopathies
    17. Future of metal chelators in AD therapy
    18. Novel dual-acting hybrids targeting type-2 cannabinoid receptors and cholinesterase activity show neuroprotective effects in vitro and amelioration of cognitive impairment in vivo
    19. Role of autophagy in neurodegeneration and aging; small molecule modulators
    20. NEW treatments on the horizon for Alzheimer’s and other neurodegenerative diseases

    Part 4. Modern biophysical methods, molecular dynamics and machine learning
    21. Intrinsically unfolded proteins and the role of protein condensation
    22. A-beta: Structure and interaction with membranes as revealed by NMR
    23. Oligomers formation by amyloid beta as studied by coarse-grain MD
    24. Machine learning in prediction of protein aggregation and/or condensation states